Home Tags Immune checkpoint inhibitors

Tag: immune checkpoint inhibitors

ESMO 2017 - 3

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial...

Results from an interim Phase II study with sacituzumab govitecan (IMMU-132) shows that the investigational agent is active in patients with metastatic urothelial cancer...

Immune Checkpoint Inhibitor Nivolumab: Five-year Survival Rate in Advanced Lung Cancer

Data from a phase I clincal trial presented at the Annual Meeting of American Association for Cancer Research (AACR), beimg held April 1-5, 2017...

Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...

Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

DOWNLOAD